Takeda Pharmaceutical Co.’s wholly-owned subsidiary, Takeda America Holdings, has entered into a definitive agreement to acquire Envoy Therapeutics for $140 million, including an upfront payment and progress-based preclinical milestones. Takeda will continue operating Envoy in Jupiter, FL through March 2013, and will transfer the majority of the scientific staff and management team to Takeda California in San Diego.   The acquisition provides Takeda with Envoy’s bacTRAP technology, which combine...